UBS Group cut shares of Sandoz Group (OTCMKTS:SDZNY - Free Report) from a strong-buy rating to a hold rating in a research report sent to investors on Monday morning,Zacks.com reports.
Separately, BNP Paribas downgraded shares of Sandoz Group from a "strong-buy" rating to a "hold" rating in a report on Monday, December 2nd.
View Our Latest Report on Sandoz Group
Sandoz Group Stock Up 0.4 %
Shares of Sandoz Group stock traded up $0.20 during trading on Monday, hitting $48.81. 63,584 shares of the stock traded hands, compared to its average volume of 46,903. The company has a fifty day moving average price of $43.52 and a two-hundred day moving average price of $43.20. Sandoz Group has a twelve month low of $27.79 and a twelve month high of $48.92.
About Sandoz Group
(
Get Free Report)
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Further Reading
Before you consider Sandoz Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandoz Group wasn't on the list.
While Sandoz Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
